Preview

Diabetes mellitus

Advanced search

The effect of vitamin D therapy on inflammatory markers in patients with type 2 diabetes mellitus and diabetic peripheral polyneuropathy

https://doi.org/10.14341/DM10316

Abstract

BACKGROUND: The pathogenesis of diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM) is multifactorial, and includes increased inflammation. In recent years, the effect of vitamin D therapy on improving the profile of inflammatory parameters has been actively studied.


AIMS: The aim of this study was to assess inflammation markers before and after various doses of cholecalciferol therapy in T2DM with DPN.


MATERIALS AND METHODS: Single-center open randomized study included T2DM patients with PDN. Sixty-seven patients were randomized into 2 groups. For 24 weeks Group I have been taking a dosage of cholecalciferol 5,000 IU/week, and Group II a dosage of 40,000 IU/week. At the baseline and in the end of the research there have been studied body mass index (BMI), glycated hemoglobin (HbA1c), 25-hydroxyvitamin D (25(OH)D), PTH, interleukin-1β, -6, -10 (IL), C-reactive protein (CRP), tumor necrosis factor -α (TNFα).


RESULTS: Sixty-two patients completed the study. Group I (n=31, F16), Group II (n=31, F15) were initially compared by age, sex, BMI and НbA1clevel. Vitamin D deficiency/insufficiency was detected in 78% of patients with T2DM. After 24 weeks of therapy with cholecalciferol in Group II there was a significant decrease in BMI, HbA1c, IL-6 levels and an increase in IL-10 levels while no changes were found in Group I. There has been established a correlation between the final level of 25(OH)D and IL-6 (r=-0.378, p=0.036), IL-10 (r=0.483, p=0.006), BMI (r=-0.388, p=0.031) and НbA1c(r=-0.388, p=0.031).


CONCLUSION: The intake of cholecalciferol at a dosage of 40,000 IU/week for 24 weeks is associated with a decrease in BMI, improvement of glycemic control and pro-inflammatory markers profile in patients with T2DM with DPN. Study results showed that the normalization of serum 25(OH)D level can be one of the modifying factors for the development and progression of DPN in patients with T2DM.

About the Authors

Anna P. Stepanova
Almazov National Medical Research Centre; Pavlov First Saint Petersburg State Medical University
Russian Federation

MD, PhD student



Tatiana L. Karonova
Almazov National Medical Research Centre; Pavlov First Saint Petersburg State Medical University
Russian Federation

MD, PhD, Professor



References

1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the american diabetes association. Diabetes Care. 2016;40(1):136–154. doi: https://doi.org/10.2337/dc16-2042

2. Cashman KD, Dowling KG, Škrabáková Z, et al. Vitamin D deficiency in Europe: pandemic? Am J Clin Nutr. 2016;103(4):1033–1044. doi: https://doi.org/10.3945/ajcn.115.120873

3. Qu GB, Wang LL, Tang X, et al. The association between vitamin D level and diabetic peripheral neuropathy in patients with type 2 diabetes mellitus: An update systematic review and meta-analysis. J Clin Transl Endocrinol. 2017;9:25–31. doi: https://doi.org/10.1016/j.jcte.2017.04.001

4. Liu E, Meigs JB, Pittas AG, et al. Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study. Am J Clin Nutr. 2010;91(6):1627−1633. doi: https://doi.org/10.3945/ajcn.2009.28441

5. Gagnon C, Lu ZX, Magliano DJ, et al. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years. Diabetes Care. 2011;34(5):1133−1138. doi: https://doi.org/10.2337/dc10-2167

6. Moreira-Lucas TS, Duncan AM, Rabasa-Lhoret R, et al. Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): a double-blind, randomized, placebo-controlled clinical trial. Diabetes Obes Metab. 2016;19(1):133–141. doi: https://doi.org/10.1111/dom.12794

7. Pittas AG, Dawson-Hughes B, Sheehan P, et al. Vitamin D supplementation and prevention of type 2 diabetes. N Engl J Med. 2019;381(6):520−530. doi: https://doi.org/10.1056/nejmoa1900906

8. Davidson MB, Duran P, Lee ML, Friedman TC. High-dose vitamin D supplementation in people with prediabetes and hypovitaminosis D. Diabetes Care. 2012;36(2):260–266. doi: https://doi.org/10.2337/dc12-1204

9. Muñoz-Garach A, García-Fontana B, Muñoz-Torres M. Vitamin D status, calcium intake and risk of developing type 2 diabetes: an unresolved issue. Nutrients. 2019;11(3):E642. doi: https://doi.org/10.3390/nu11030642

10. Jamwal S, Sharma S. Vascular endothelium dysfunction: a conservative target in metabolic disorders. Inflamm Res. 2018;67(5):391−405. doi: 10.1007/s00011-018-1129-8.

11. Magrinelli F, Briani C, Romano M, et al. The association between serum cytokines and damage to large and small nerve fibers in diabetic peripheral neuropathy. J Diab Res. 2015;2015:547834. doi: https://doi.org/10.1155/2015/547834.41

12. Pop-Busui R, Ang L, Holmes C, et al. Inflammation as a therapeutic target for diabetic neuropathies. Curr Diab Rep. 2016;16(3):29. doi: https://doi.org/10.1007/s11892-016-0727-5

13. Alamdari A, Mozafari R, Tafakhori A, et al. An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects. Neurol Sci. 2015;36(7):1121−1126. doi: https://doi.org/10.1007/s10072-015-2207-0

14. He R, Hu Y, Zeng H, et al. Vitamin D deficiency increases the risk of peripheral neuropathy in Chinese patients with Type 2 diabetes. Diab Metab Res Rev. 2017;33(2):e2820. doi: https://doi.org/10.1002/dmrr.2820

15. Celikbilek A, Gocmen AY, Tanik N, et al. Decreased serum vitamin D levels are associated with diabetic peripheral neuropathy in a rural area of Turkey. Acta Neurol Belgica. 2015;115(1):47−52. doi: https://doi.org/10.1007/s13760-014-0304-0

16. Bilir B, Tulubas F, Bilir BE, et al. The association of vitamin D with inflammatory cytokines in diabetic peripheral neuropathy. J Physical Ther Sci. 2016;28(7):2159–2163. doi: https://doi.org/10.1589/jpts.28.2159

17. Randhawa FA, Mustafa S, Khan DM, Hamid S. Effect of vitamin D supplementation on reduction in levels of HbA1 in patients recently diagnosed with type 2 diabetes mellitus having asymptomatic vitamin D deficiency. Pakistan J Med Sci. 2017;33(4):881−885. doi: https://doi.org/10.12669/pjms.334.12288.48

18. Basit A, Basit KA, Fawwad A, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diab Res Care. 2016;4(1):e000148. doi: https://doi.org/10.1136/bmjdrc-2015-000148

19. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 8-й вып. // Сахарный диабет. — 2017. — Т. 20. — №1S. — C. 1–121. [Dedov II, Shestakova MV, Mayorov AY, et al. Standards of specialized diabetes care. Ed. by Dedov II, Shestakova MV, Mayorov AY. 8th ed. Diabetes Milletus. 2017;20(1S):1–121. (In Russ).] doi: https://doi.org/10.14341/DM20171S8

20. Гурьева И.В., Комелягина Е.Ю., Кузина И.В., Ахметов А.С. Диабетическая периферическая сенсомоторная нейропатия. Патогенез, клиника и диагностика. Методические рекомендации. — М., 2000. — 23 с. [Gur’yeva IV, Komelyagina EYu, Kuzina IV, Akhmetov AS. Diabeticheskaya perifericheskaya sensomotornaya neyropatiya. Patogenez, klinika i diagnostika. Metodicheskiye rekomendatsii. Moscow; 2000. 23 р. (In Russ).]

21. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short-Form McGill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S240–252. doi: https://doi.org/10.1002/acr.20543

22. Бреговский В.Б., Храмилин В.Н., Демидова И.Ю., и др. Диабетическая дистальная полинейропатия. Обзор современных рекомендаций // Анналы клинической и экспериментальной неврологии. — 2015. — Т. 9. — №1. — С. 60−68. [Beregovsky VB, Khramilin VN, Demidova IYu, et al. Distal diabetic neuropathy: review of evidence-based recommendations. Annals of Clinical and Experimental Neurology. 2015;9(1):60−68. (In Russ).]

23. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых // Проблемы эндокринологии. — 2016. — Т. 62. — №4. — С. 60−84. [Pigarova EA, Rozhinskaia LYa, Belaia ZhE, et al. Klinicheskie rekomendatsii Rossiiskoi Assotsiatsii Endokrinologov po diagnostike, lecheniiu i profilaktike defitsita vitamina D u vzroslykh. Problemy endokrinologii. 2016;62(4):60–84. (In Russ).] doi: https://doi.org/10.14341/probl201662460-84

24. Karonova T, Andreeva A, Nikitina I, et al. Prevalence of vitamin D deficiency in the North-West region of Russia: a cross-sectional study. J Steroid Biochem Mol Biol. 2016;164:230−234. doi: https://doi.org/10.1016/j.jsbmb.2016.03.026

25. Maddaloni E, Cavallari I, Napoli N, Conte C. Vitamin D and diabetes mellitus. Front Horm Res. 2018;50:161−176. doi: https://doi.org/10.1159/000486083.

26. Lips P, Eekhoff M, van Schoor N, et al. Vitamin D and type 2 diabetes. J Steroid Biochem Mol Biol. 2017;173:280–285. doi: https://doi.org/10.1016/j.jsbmb.2016.11.021

27. Коденцова В.М., Намазова-Баранова Л.С., Макарова С.Г. Национальная программа по оптимизации обеспеченности витаминами и минеральными веществами детей России. Краткий обзор документа // Педиатрическая фармакология. — 2017. — Т. 14. — №6. — С. 478−493. [Kodentsova VM, Namazova-Baranova LS, Makarova SG. The national program for optimization of provision with vitamins and minerals of children in Russia. Summary review of the document. Pediatric pharmacology. 2017;14(6):478−493. (In Russ).] doi: https://doi.org/10.15690/pf.v14i6.1831

28. Aspray TJ, Bowring C, Fraser W, et al. National osteoporosis society vitamin D guideline summary. Age Ageing. 2014;43(5):592–595. doi: https://doi.org/10.1093/ageing/afu093

29. Manson JE, Cook NR, Lee IM, et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med. 2019;380(1):23–32. doi: https://doi.org/10.1056/nejmoa1811403

30. Chapman D, Foxcroft R, Dale-Harris L, et al. Insights for care: the healthcare utilisation and cost impact of managing type 2 diabetes-associated microvascular complications. Diab Ther. 2019;10(2):575–585. doi: https://doi.org/10.1007/s13300-018-0548-4

31. Calton EK, Keane KN, Newsholme P, Soares MJ. The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies. PLoS One. 2015;10(11):e0141770. doi: https://doi.org/10.1371/journal.pone.0141770

32. Степанова А.П., Каронова Т.Л., Быстрова А.А., Бреговский В.Б. Роль дефицита витамина D в развитии сахарного диабета 2 типа и диабетической нейропатии // Сахарный диабет. — 2018. — Т. 21. — №4. — С. 301−306. [Stepanova AP, Karonova TL, Bystrova AA, Bregovsky VB. Role of vitamin D deficiency in type 2 diabetes mellitus and diabetic neuropathy development. Diabetes Mellitus. 2018;21(4):301−306. (In Russ).] doi: https://doi.org/10.14341/dm9583

33. Zeng J, Xu Y, Shi Y, Jiang C. Inflammation role in sensory neuropathy in Chinese patients with diabetes/prediabetes. Clin Neurol Neurosurg. 2018;166:136–140. doi: https://doi.org/10.1016/j.clineuro.2018.01.031

34. Mazidi M, Toth PP, Banach M. C-reactive protein is associated with prevalence of the metabolic syndrome, hypertension, and diabetes mellitus in US adults. Angiology. 2017;69(5):438–442. doi: https://doi.org/10.1177/0003319717729288

35. Salekzamani S, Bavil AS, Mehralizadeh H, et al. The effects of vitamin D supplementation on proatherogenic inflammatory markers and carotid intima media thickness in subjects with metabolic syndrome: a randomized double-blind placebo-controlled clinical trial. Endocrine. 2017;57(1):51–59. doi: https://doi.org/10.1007/s12020-017-1317-2

36. Jackson JL, Judd SE, Panwar B, et al. Associations of 25-hydroxyvitamin D with markers of inflammation, insulin resistance and obesity in black and white community-dwelling adults. J Clin Transl Endocrinol. 2016;5:21–25. doi: https://doi.org/10.1016/j.jcte.2016.06.002

37. Mousa A, Naderpoor N, Teede H, et al. Vitamin D supplementation for improvement of chronic low-grade inflammation in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev. 2018;76(5):380–394. doi: https://doi.org/10.1093/nutrit/nux077

38. Colotta F, Jansson B, Bonelli F. Modulation of inflammatory and immune responses by vitamin D. J Autoimm. 2017;85:78–97. doi: https://doi.org/10.1016/j.jaut.2017.07.007


Supplementary files

1. Таблица 1
Subject
Type Исследовательские инструменты
Download (15KB)    
Indexing metadata ▾
2. Таблица 2
Subject
Type Исследовательские инструменты
Download (15KB)    
Indexing metadata ▾
3. Fig. 1. Dynamics of indicators of the level of 25-hydroxyvitamin D in the blood serum against the background of a 24-week intake of colecalciferol.
Subject
Type Other
View (177KB)    
Indexing metadata ▾
4. Fig. 2. Dynamics of indicators of the levels of IL-6 and IL-10 during therapy with various doses of colecalciferol for 24 weeks.
Subject
Type Other
View (322KB)    
Indexing metadata ▾

Review

For citations:


Stepanova A.P., Karonova T.L. The effect of vitamin D therapy on inflammatory markers in patients with type 2 diabetes mellitus and diabetic peripheral polyneuropathy. Diabetes mellitus. 2019;22(5):417-427. (In Russ.) https://doi.org/10.14341/DM10316

Views: 2992


ISSN 2072-0351 (Print)
ISSN 2072-0378 (Online)